Associate Professor Alexander Menzies

BSc(Med) MBBS(Hons) FRACP PhD
Cancer Instutute NSW Senior Research Fellow - Medicine, Northern Clinical School

Telephone (02) 9911 7210
Fax (02) 9954 9418
Curriculum vitae Curriculum vitae

Map

Selected grants

2018

  • The Role of Tumour-Resident CD8+ T cells in Metastatic Melanoma and Immunotherapy; Palendira U, Wilmott J, Menzies A, Luciani F, Gebhardt T; Cancer Council New South Wales/Research Grant.
  • Predictive biomarkers of response to immunotherapy in melanoma; Menzies A, Long G; Cancer Institute New South Wales/Early Career Fellowship.

2017

  • Nutrient stress-mediated adaptive responses as novel targets in BRAF mutant melanoma; Holst J, Wilmott J, Menzies A; Cancer Council New South Wales/Research Project Grants.
  • Determinants of response to immune checkpoint inhibitors in melanoma; Rizos H, Long G, Fazekas de St Groth B, Menzies A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Acquired resistance to PD1 inhibition in melanoma; Rizos H, Menzies A; National Health and Medical Research Council (NHMRC)/Project Grants.

2015

  • Identifying predictive biomarkers of current systemic therapies and the discovery of new targets and future treatments to improve survival in metastatic melanoma.; Menzies A; Cancer Institute New South Wales/Early Career Fellowship.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Lee, J., Long, G., Menzies, A., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R., Rizos, H., Carlino, M. (2018). Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncology, 4(5), 717-721. [More Information]
  • McQuade, J., Daniel, C., Hess, K., Mak, C., Wang, D., Rai, R., Park, J., Haydu, L., Spencer, C., Wongchenko, M., Carlino, M., Long, G., Menzies, A., et al (2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet Oncology, 19(3), 310-322. [More Information]
  • Edwards, J., Wilmott, J., Madore, J., Gide, T., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., Weninger, W., Britton, W., Saw, R., Thompson, J., Menzies, A., Long, G., Scolyer, R., Palendira, U., et al (2018). CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. Clinical Cancer Research, 24(13), 3036-3045. [More Information]
  • Long, G., Atkinson, V., Lo, S., Sandhu, S., Guminski, A., Brown, M., Wilmott, J., Edwards, J., Gonzalez, M., Scolyer, R., Menzies, A., et al (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19(5), 672-681. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Corrigendum to Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]". European Journal of Cancer, 93, 158. [More Information]
  • De Sousa, S., Sheriff, N., Tran, C., Menzies, A., Tsang, V., Long, G., Tonks, K. (2018). Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary, 21(3), 274-282. [More Information]
  • Johnson, D., Sullivan, R., Menzies, A. (2018). Immune checkpoint inhibitors in challenging populations. Cancer, 123(11), 1904-1911. [More Information]
  • Arasaratnam, M., Hong, A., Shivalingam, B., Wheeler, H., Guminski, A., Long, G., Menzies, A. (2018). Leptomeningeal melanoma - a case series in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(1), 120-124. [More Information]
  • Lee, J., Lyle, M., Menzies, A., Chan, M., Lo, S., Clements, A., Carlino, M., Kefford, R., Long, G. (2018). Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell & Melanoma Research, 31(3), 404-410. [More Information]
  • Tetzlaff, M., Messina, J., Stein, J., Xu, X., Amaria, R., Blank, C., van de Wiel, B., Ferguson, P., Rawson, R., Ross, M., Spillane, A., Saw, R., Menzies, A., Long, G., Scolyer, R., et al (2018). Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 29(8), 1861-1868. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 91, 116-124. [More Information]
  • Pollack, M., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A., Ancell, K., Long, G., Menzies, A., Eroglu, Z., et al (2018). Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Annals of Oncology, 29(1), 250-255. [More Information]
  • Tio, M., Wang, X., Carlino, M., Shivalingam, B., Fogarty, G., Guminski, A., Lo, S., Hong, A., Menzies, A., Long, G. (2018). Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(4), 509-515. [More Information]
  • Scott, E., Long, G., Guminski, A., Clifton-Bligh, R., Menzies, A., Tsang, V. (2018). The Spectrum, Incidence, Kinetics, and Management of Endocrinopathies with Immune Checkpoint Inhibitors for Metastatic Melanoma. European Journal of Endocrinology, 178(2), 175-182. [More Information]
  • Itchins, M., Ascierto, P., Menzies, A., Oatley, M., Lo, S., Douraghi-Zadeh, D., Harrington, T., Maher, R., Grimaldi, A., Guminski, A. (2017). A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 27(3), 243-250. [More Information]
  • Liang, R., Meiser, B., Smith, S., Kasparian, N., Lewis, C., Chin, M., Long, G., Ward, R., Menzies, A., Harris-Wai, J., et al (2017). Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. European Journal of Cancer Care, 26(6), 1-11. [More Information]
  • Menzies, A., Johnson, D., Ramanujam, S., Atkinson, V., Wong, A., Park, J., McQuade, J., Shoushtari, A., Tsai, K., Eroglu, Z., Guminski, A., Carlino, M., Long, G., et al (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28(2), 368-376. [More Information]
  • Lee, J., Long, G., Boyd, S., Lo, S., Menzies, A., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R., Mann, G., Kefford, R., Carlino, M., Rizos, H. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130-1136. [More Information]
  • Pupo, G., Boyd, S., Fung, C., Carlino, M., Menzies, A., Pedersen, B., Johansson, P., Hayward, N., Kefford, R., Scolyer, R., Long, G., Rizos, H. (2017). Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomarker Research, 5(17), 1-4. [More Information]
  • Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G., Scolyer, R. (2017). Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clinical Cancer Research, 23(17), 5024-5033. [More Information]
  • Parakh, S., Park, J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C., Wong, A., McArthur, G., Guminski, A., Kefford, R., Long, G., Menzies, A., Carlino, M., et al (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 116(12), 1558-1563. [More Information]
  • Lim, S., Lee, J., Welsh, S., Ahn, S., Breen, E., Khan, A., Carlino, M., Menzies, A., Kefford, R., Scolyer, R., Long, G., et al (2017). Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 5, 1-12. [More Information]
  • Tan, A., Heimberger, A., Menzies, A., Pavlakis, N., Khasraw, M. (2017). Immune Checkpoint Inhibitors for Brain Metastases. Current Oncology Reports, 19(6), 1-12. [More Information]
  • Gu, Y., Menzies, A., Long, G., Fernando, S., Herkes, G. (2017). Immune mediated neuropathy following checkpoint immunotherapy. Journal of Clinical Neuroscience, 45, 14-17. [More Information]
  • Lim, S., Menzies, A., Rizos, H. (2017). Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 123(S11), 2118-2129. [More Information]
  • Kakavand, H., Jackett, L., Menzies, A., Gide, T., Carlino, M., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2017). Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 30(12), 1666-1676. [More Information]
  • Menzies, A., Long, G. (2017). Optimum dosing of ipilimumab in melanoma: too little, too late? The Lancet Oncology, 18(5), 558-559. [More Information]
  • Kakavand, H., Rawson, R., Pupo, G., Yang, J., Menzies, A., Carlino, M., Kefford, R., Howle, J., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R., et al (2017). PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clinical Cancer Research, 23(20), 6054-6061. [More Information]
  • Naidoo, J., Wang, X., Woo, K., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J., Segal, N., Callahan, M., Lesokhin, A., Menzies, A., Carlino, M., Kong, B., Long, G., et al (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. [More Information]
  • Sidhu, P., Menzies, A., Long, G., Carlino, M., Lorens, S., Kapoor, R. (2017). Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. Journal of Medical Imaging and Radiation Oncology, 61(6), 759-766. [More Information]
  • Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]
  • Choong, E., Lo, S., Drummond, M., Fogarty, G., Menzies, A., Guminski, A., Shivalingam, B., Clarke, K., Long, G., Hong, A. (2017). Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. European Journal of Cancer, 75, 169-178. [More Information]
  • Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
  • Carlino, M., Vanella, V., Girgis, C., Giannarelli, D., Guminski, A., Festino, L., Kefford, R., Menzies, A., Long, G., Ascierto, P. (2016). Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series. British Journal of Cancer, 115(11), 1280-1284. [More Information]
  • De Paoli-Iseppi, R., Johansson, P., Menzies, A., Dias, K., Pupo, G., Kakavand, H., Wilmott, J., Mann, G., Hayward, N., Dinger, M., Long, G., Scolyer, R. (2016). Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 48(3), 261-266. [More Information]
  • Fox, P., Balleine, R., Lee, C., Gao, B., Balakrishnar, B., Menzies, A., Yeap, S., Ali, S., Gebski, V., Provan, P., Liddle, C., Hui, R., Kefford, R., Wong, K., Wilcken, N., Gurney, H., et al (2016). Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study. Clinical Cancer Research, 22(13), 3164-3171. [More Information]
  • Johnson, D., Sullivan, R., Ott, P., Carlino, M., Khushalani, N., Ye, F., Guminski, A., Puzanov, I., Lawrence, D., Buchbinder, E., Menzies, A., Long, G., et al (2016). Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2(2), 234-240. [More Information]
  • Atkinson, V., Long, G., Menzies, A., McArthur, G., Carlino, M., Millward, M., Roberts-Thomson, R., Brady, B., Kefford, R., Haydon, A., et al (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 12(Suppl. 7), 5-12. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Menzies, A., Long, G. (2016). Recent Developments in Melanoma Therapy. JAMA Oncology, 2(10), 1259-1260. [More Information]
  • Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]
  • Kaur, A., Webster, M., Marchbank, K., Behera, R., Ndoye, A., Kugel III, C., Dang, V., Appleton, J., O'Connell, M., Menzies, A., Long, G., et al (2016). sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 532, 250-254. [More Information]
  • Lyle, M., Haydu, L., Menzies, A., Thompson, J., Saw, R., Spillane, A., Kefford, R., Mann, G., Cooper, W., Yu, B., Scolyer, R., O'Toole, S., Long, G. (2016). The molecular profile of metastatic melanoma in Australia. Pathology, 48(2), 188-193. [More Information]
  • Johnson, D., Menzies, A., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R., Gutzmer, R., Kefford, R., Thompson, J., Pupo, G., Long, G., et al (2015). Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 51(18), 2792-2799. [More Information]
  • Menzies, A., Ashworth, M., Swann, S., Kefford, R., Flaherty, K., Weber, J., Infante, J., Kim, K., Gonzalez, R., Hamid, O., Long, G., et al (2015). Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial. Annals of Oncology, 26(2), 415-421. [More Information]
  • Menzies, A., Yeh, I., Botton, T., Bastian, B., Scolyer, R., Long, G. (2015). Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell & Melanoma Research, 28(5), 607-610. [More Information]
  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Carlos Minano, G., Anforth, R., Clements, A., Menzies, A., Carlino, M., Chou, S., Fernandez Penas, P. (2015). Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 151(10), 1103-1109. [More Information]
  • Wang, J., Huang, S., Marzese, D., Hsu, S., Kawas, N., Chong, K., Long, G., Menzies, A., Scolyer, R., Izraely, S., et al (2015). Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. Journal of Investigative Dermatology, 135(2), 532-541. [More Information]
  • Anforth, R., Menzies, A., Byth Wilson, K., Carlos Minano, G., Chou, S., Sharma, R., Scolyer, R., Kefford, R., Long, G., Fernandez Penas, P. (2015). Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal Of The American Academy Of Dermatology, 72(5), 809-815.e1. [More Information]
  • Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
  • Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
  • Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
  • Menzies, A., Long, G. (2014). Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 20(8), 2035-2043. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Lezcano, C., Lee, C., Larson, A., Menzies, A., Kefford, R., Thompson, J., Mihm, M., Ogino, S., Long, G., Scolyer, R., et al (2014). Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 27(9), 1193-1202. [More Information]
  • Lee, C., Menzies, A., Haydu, L., Azer, M., Clements, A., Kefford, R., Long, G. (2014). Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research, 24(5), 468-474. [More Information]
  • Zimmer, L., Haydu, L., Menzies, A., Scolyer, R., Kefford, R., Thompson, J., Schadendorf, D., Long, G. (2014). Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 32(8), 816-823. [More Information]
  • Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 5, 1-9. [More Information]
  • Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PloS One, 9(1), 1-9. [More Information]
  • Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra-patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678-1679. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Ackerman, A., Klein, O., McDermott, D., Wang, W., Ibrahim, N., Lawrence, D., Gunturi, A., Flaherty, K., Hodi, F., Kefford, R., Menzies, A., Long, G., et al (2014). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 120(11), 1695-1701. [More Information]
  • Azer, M., Menzies, A., Haydu, L., Kefford, R., Long, G. (2014). Patterns of Response and Progression in Patients With BRAF-Mutant Melanoma Metastatic to the Brain Who Were Treated With Dabrafenib. Cancer, 120(4), 530-536. [More Information]
  • Zimmer, L., Haydu, L., Menzies, A., Scolyer, R., Kefford, R., Thompson, J., Schadendorf, D., Long, G. (2014). Reply to M. Perier-Muzet et al. Journal of Clinical Oncology, 32(28), 3203-3204. [More Information]
  • Menzies, A., Long, G. (2014). Systemic treatment for BRAF-mutant melanoma: where do we go next? The Lancet Oncology, 15(9), e371-e381. [More Information]
  • Chan, M., Haydu, L., Menzies, A., Azer, M., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R., Long, G. (2014). The nature and management of metastatic melanoma after progression on braf inhibitors: Effects of extended BRAF inhibition. Cancer, 120(20), 3142-3153. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma – Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Thompson, J., Menzies, A. (2013). Melanoma. Cancer Forum, 37(1), 65-66.
  • Menzies, A., Long, G. (2013). New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Therapeutic Advances in Medical Oncology, 5(5), 278-285. [More Information]
  • Menzies, A., Kefford, R., Long, G. (2013). Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell & Melanoma Research, 26(5), 611-615. [More Information]
  • Menzies, A., Long, G. (2013). Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer, 49(15), 3229-3241. [More Information]
  • Menzies, A., Long, G. (2012). Clinicopathologic features of V600E and V600K melanoma - Response. Clinical Cancer Research, 18(24), 6793-6793. [More Information]
  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 18(12), 3242-3249. [More Information]

2018

  • Lee, J., Long, G., Menzies, A., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R., Rizos, H., Carlino, M. (2018). Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncology, 4(5), 717-721. [More Information]
  • McQuade, J., Daniel, C., Hess, K., Mak, C., Wang, D., Rai, R., Park, J., Haydu, L., Spencer, C., Wongchenko, M., Carlino, M., Long, G., Menzies, A., et al (2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet Oncology, 19(3), 310-322. [More Information]
  • Edwards, J., Wilmott, J., Madore, J., Gide, T., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., Weninger, W., Britton, W., Saw, R., Thompson, J., Menzies, A., Long, G., Scolyer, R., Palendira, U., et al (2018). CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. Clinical Cancer Research, 24(13), 3036-3045. [More Information]
  • Long, G., Atkinson, V., Lo, S., Sandhu, S., Guminski, A., Brown, M., Wilmott, J., Edwards, J., Gonzalez, M., Scolyer, R., Menzies, A., et al (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet Oncology, 19(5), 672-681. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Corrigendum to Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]". European Journal of Cancer, 93, 158. [More Information]
  • De Sousa, S., Sheriff, N., Tran, C., Menzies, A., Tsang, V., Long, G., Tonks, K. (2018). Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary, 21(3), 274-282. [More Information]
  • Johnson, D., Sullivan, R., Menzies, A. (2018). Immune checkpoint inhibitors in challenging populations. Cancer, 123(11), 1904-1911. [More Information]
  • Arasaratnam, M., Hong, A., Shivalingam, B., Wheeler, H., Guminski, A., Long, G., Menzies, A. (2018). Leptomeningeal melanoma - a case series in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(1), 120-124. [More Information]
  • Lee, J., Lyle, M., Menzies, A., Chan, M., Lo, S., Clements, A., Carlino, M., Kefford, R., Long, G. (2018). Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell & Melanoma Research, 31(3), 404-410. [More Information]
  • Tetzlaff, M., Messina, J., Stein, J., Xu, X., Amaria, R., Blank, C., van de Wiel, B., Ferguson, P., Rawson, R., Ross, M., Spillane, A., Saw, R., Menzies, A., Long, G., Scolyer, R., et al (2018). Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 29(8), 1861-1868. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 91, 116-124. [More Information]
  • Pollack, M., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A., Ancell, K., Long, G., Menzies, A., Eroglu, Z., et al (2018). Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Annals of Oncology, 29(1), 250-255. [More Information]
  • Tio, M., Wang, X., Carlino, M., Shivalingam, B., Fogarty, G., Guminski, A., Lo, S., Hong, A., Menzies, A., Long, G. (2018). Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(4), 509-515. [More Information]
  • Scott, E., Long, G., Guminski, A., Clifton-Bligh, R., Menzies, A., Tsang, V. (2018). The Spectrum, Incidence, Kinetics, and Management of Endocrinopathies with Immune Checkpoint Inhibitors for Metastatic Melanoma. European Journal of Endocrinology, 178(2), 175-182. [More Information]

2017

  • Itchins, M., Ascierto, P., Menzies, A., Oatley, M., Lo, S., Douraghi-Zadeh, D., Harrington, T., Maher, R., Grimaldi, A., Guminski, A. (2017). A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 27(3), 243-250. [More Information]
  • Liang, R., Meiser, B., Smith, S., Kasparian, N., Lewis, C., Chin, M., Long, G., Ward, R., Menzies, A., Harris-Wai, J., et al (2017). Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. European Journal of Cancer Care, 26(6), 1-11. [More Information]
  • Menzies, A., Johnson, D., Ramanujam, S., Atkinson, V., Wong, A., Park, J., McQuade, J., Shoushtari, A., Tsai, K., Eroglu, Z., Guminski, A., Carlino, M., Long, G., et al (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28(2), 368-376. [More Information]
  • Lee, J., Long, G., Boyd, S., Lo, S., Menzies, A., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R., Mann, G., Kefford, R., Carlino, M., Rizos, H. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130-1136. [More Information]
  • Pupo, G., Boyd, S., Fung, C., Carlino, M., Menzies, A., Pedersen, B., Johansson, P., Hayward, N., Kefford, R., Scolyer, R., Long, G., Rizos, H. (2017). Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomarker Research, 5(17), 1-4. [More Information]
  • Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G., Scolyer, R. (2017). Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clinical Cancer Research, 23(17), 5024-5033. [More Information]
  • Parakh, S., Park, J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C., Wong, A., McArthur, G., Guminski, A., Kefford, R., Long, G., Menzies, A., Carlino, M., et al (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 116(12), 1558-1563. [More Information]
  • Lim, S., Lee, J., Welsh, S., Ahn, S., Breen, E., Khan, A., Carlino, M., Menzies, A., Kefford, R., Scolyer, R., Long, G., et al (2017). Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 5, 1-12. [More Information]
  • Tan, A., Heimberger, A., Menzies, A., Pavlakis, N., Khasraw, M. (2017). Immune Checkpoint Inhibitors for Brain Metastases. Current Oncology Reports, 19(6), 1-12. [More Information]
  • Gu, Y., Menzies, A., Long, G., Fernando, S., Herkes, G. (2017). Immune mediated neuropathy following checkpoint immunotherapy. Journal of Clinical Neuroscience, 45, 14-17. [More Information]
  • Lim, S., Menzies, A., Rizos, H. (2017). Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 123(S11), 2118-2129. [More Information]
  • Kakavand, H., Jackett, L., Menzies, A., Gide, T., Carlino, M., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2017). Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 30(12), 1666-1676. [More Information]
  • Menzies, A., Long, G. (2017). Optimum dosing of ipilimumab in melanoma: too little, too late? The Lancet Oncology, 18(5), 558-559. [More Information]
  • Kakavand, H., Rawson, R., Pupo, G., Yang, J., Menzies, A., Carlino, M., Kefford, R., Howle, J., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R., et al (2017). PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clinical Cancer Research, 23(20), 6054-6061. [More Information]
  • Naidoo, J., Wang, X., Woo, K., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J., Segal, N., Callahan, M., Lesokhin, A., Menzies, A., Carlino, M., Kong, B., Long, G., et al (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. [More Information]
  • Sidhu, P., Menzies, A., Long, G., Carlino, M., Lorens, S., Kapoor, R. (2017). Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. Journal of Medical Imaging and Radiation Oncology, 61(6), 759-766. [More Information]
  • Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]
  • Choong, E., Lo, S., Drummond, M., Fogarty, G., Menzies, A., Guminski, A., Shivalingam, B., Clarke, K., Long, G., Hong, A. (2017). Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. European Journal of Cancer, 75, 169-178. [More Information]

2016

  • Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
  • Carlino, M., Vanella, V., Girgis, C., Giannarelli, D., Guminski, A., Festino, L., Kefford, R., Menzies, A., Long, G., Ascierto, P. (2016). Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series. British Journal of Cancer, 115(11), 1280-1284. [More Information]
  • De Paoli-Iseppi, R., Johansson, P., Menzies, A., Dias, K., Pupo, G., Kakavand, H., Wilmott, J., Mann, G., Hayward, N., Dinger, M., Long, G., Scolyer, R. (2016). Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 48(3), 261-266. [More Information]
  • Fox, P., Balleine, R., Lee, C., Gao, B., Balakrishnar, B., Menzies, A., Yeap, S., Ali, S., Gebski, V., Provan, P., Liddle, C., Hui, R., Kefford, R., Wong, K., Wilcken, N., Gurney, H., et al (2016). Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study. Clinical Cancer Research, 22(13), 3164-3171. [More Information]
  • Johnson, D., Sullivan, R., Ott, P., Carlino, M., Khushalani, N., Ye, F., Guminski, A., Puzanov, I., Lawrence, D., Buchbinder, E., Menzies, A., Long, G., et al (2016). Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2(2), 234-240. [More Information]
  • Atkinson, V., Long, G., Menzies, A., McArthur, G., Carlino, M., Millward, M., Roberts-Thomson, R., Brady, B., Kefford, R., Haydon, A., et al (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 12(Suppl. 7), 5-12. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Menzies, A., Long, G. (2016). Recent Developments in Melanoma Therapy. JAMA Oncology, 2(10), 1259-1260. [More Information]
  • Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]
  • Kaur, A., Webster, M., Marchbank, K., Behera, R., Ndoye, A., Kugel III, C., Dang, V., Appleton, J., O'Connell, M., Menzies, A., Long, G., et al (2016). sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 532, 250-254. [More Information]
  • Lyle, M., Haydu, L., Menzies, A., Thompson, J., Saw, R., Spillane, A., Kefford, R., Mann, G., Cooper, W., Yu, B., Scolyer, R., O'Toole, S., Long, G. (2016). The molecular profile of metastatic melanoma in Australia. Pathology, 48(2), 188-193. [More Information]

2015

  • Johnson, D., Menzies, A., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R., Gutzmer, R., Kefford, R., Thompson, J., Pupo, G., Long, G., et al (2015). Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 51(18), 2792-2799. [More Information]
  • Menzies, A., Ashworth, M., Swann, S., Kefford, R., Flaherty, K., Weber, J., Infante, J., Kim, K., Gonzalez, R., Hamid, O., Long, G., et al (2015). Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial. Annals of Oncology, 26(2), 415-421. [More Information]
  • Menzies, A., Yeh, I., Botton, T., Bastian, B., Scolyer, R., Long, G. (2015). Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell & Melanoma Research, 28(5), 607-610. [More Information]
  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Carlos Minano, G., Anforth, R., Clements, A., Menzies, A., Carlino, M., Chou, S., Fernandez Penas, P. (2015). Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 151(10), 1103-1109. [More Information]
  • Wang, J., Huang, S., Marzese, D., Hsu, S., Kawas, N., Chong, K., Long, G., Menzies, A., Scolyer, R., Izraely, S., et al (2015). Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. Journal of Investigative Dermatology, 135(2), 532-541. [More Information]
  • Anforth, R., Menzies, A., Byth Wilson, K., Carlos Minano, G., Chou, S., Sharma, R., Scolyer, R., Kefford, R., Long, G., Fernandez Penas, P. (2015). Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal Of The American Academy Of Dermatology, 72(5), 809-815.e1. [More Information]
  • Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
  • Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.

2014

  • Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
  • Menzies, A., Long, G. (2014). Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 20(8), 2035-2043. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Lezcano, C., Lee, C., Larson, A., Menzies, A., Kefford, R., Thompson, J., Mihm, M., Ogino, S., Long, G., Scolyer, R., et al (2014). Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 27(9), 1193-1202. [More Information]
  • Lee, C., Menzies, A., Haydu, L., Azer, M., Clements, A., Kefford, R., Long, G. (2014). Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research, 24(5), 468-474. [More Information]
  • Zimmer, L., Haydu, L., Menzies, A., Scolyer, R., Kefford, R., Thompson, J., Schadendorf, D., Long, G. (2014). Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 32(8), 816-823. [More Information]
  • Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 5, 1-9. [More Information]
  • Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PloS One, 9(1), 1-9. [More Information]
  • Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra-patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678-1679. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Ackerman, A., Klein, O., McDermott, D., Wang, W., Ibrahim, N., Lawrence, D., Gunturi, A., Flaherty, K., Hodi, F., Kefford, R., Menzies, A., Long, G., et al (2014). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 120(11), 1695-1701. [More Information]
  • Azer, M., Menzies, A., Haydu, L., Kefford, R., Long, G. (2014). Patterns of Response and Progression in Patients With BRAF-Mutant Melanoma Metastatic to the Brain Who Were Treated With Dabrafenib. Cancer, 120(4), 530-536. [More Information]
  • Zimmer, L., Haydu, L., Menzies, A., Scolyer, R., Kefford, R., Thompson, J., Schadendorf, D., Long, G. (2014). Reply to M. Perier-Muzet et al. Journal of Clinical Oncology, 32(28), 3203-3204. [More Information]
  • Menzies, A., Long, G. (2014). Systemic treatment for BRAF-mutant melanoma: where do we go next? The Lancet Oncology, 15(9), e371-e381. [More Information]
  • Chan, M., Haydu, L., Menzies, A., Azer, M., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R., Long, G. (2014). The nature and management of metastatic melanoma after progression on braf inhibitors: Effects of extended BRAF inhibition. Cancer, 120(20), 3142-3153. [More Information]

2013

  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma – Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Thompson, J., Menzies, A. (2013). Melanoma. Cancer Forum, 37(1), 65-66.
  • Menzies, A., Long, G. (2013). New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Therapeutic Advances in Medical Oncology, 5(5), 278-285. [More Information]
  • Menzies, A., Kefford, R., Long, G. (2013). Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell & Melanoma Research, 26(5), 611-615. [More Information]
  • Menzies, A., Long, G. (2013). Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer, 49(15), 3229-3241. [More Information]

2012

  • Menzies, A., Long, G. (2012). Clinicopathologic features of V600E and V600K melanoma - Response. Clinical Cancer Research, 18(24), 6793-6793. [More Information]
  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 18(12), 3242-3249. [More Information]

To update your profile click here. For support on your academic profile contact .